Medtronic Net Debt Growth & History (MDT)
Medtronic's net debt was $25.41B for fiscal 2026.
View full Medtronic company overviewMedtronic annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-24 | $25.41B | $879.0M | +3.58% |
| 2025 | 2025-04-25 | $24.53B | −$212.0M | −0.86% |
| 2024 | 2024-04-26 | $24.75B | $895.0M | +3.75% |
| 2023 | 2023-04-28 | $23.85B | $6.32B | +36.06% |
| 2022 | 2022-04-29 | $17.53B | −$6.27B | −26.35% |
| 2021 | 2021-04-30 | $23.80B | $2.03B | +9.32% |
| 2020 | 2020-04-24 | $21.77B | $758.0M | +3.61% |
| 2019 | 2019-04-26 | $21.01B | −$1.07B | −4.84% |
| 2018 | 2018-04-27 | $22.08B | −$6.35B | −22.32% |
| 2017 | 2017-04-28 | $28.43B | $366.0M | +1.30% |
| 2016 | 2016-04-29 | $28.06B | −$2.70B | −8.78% |
| 2015 | 2015-04-24 | $30.76B | $21.85B | +245.18% |
| 2014 | 2014-04-25 | $8.91B | — | — |
Medtronic quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-07-31 | $23.93B | −$980.0M | −3.93% |
| Q4 2026 | 2026-04-24 | $25.41B | $879.0M | +3.58% |
| Q3 2026 | 2026-01-31 | $26.92B | $4.18B | +18.37% |
| Q3 2026 | 2026-01-23 | $26.73B | $3.99B | +17.53% |
| Q2 2026 | 2025-10-24 | $26.40B | $3.19B | +13.72% |
| Q1 2026 | 2025-07-25 | $24.91B | −$95.0M | −0.38% |
| Q4 2025 | 2025-04-25 | $24.53B | −$212.0M | −0.86% |
| Q3 2025 | 2025-01-24 | $22.75B | $215.0M | +0.95% |
| Q2 2025 | 2024-10-25 | $23.21B | $783.0M | +3.49% |
| Q1 2025 | 2024-07-26 | $25.00B | $1.88B | +8.12% |
| Q4 2024 | 2024-04-26 | $24.75B | $895.0M | +3.75% |
| Q3 2024 | 2024-01-26 | $22.53B | $4.84B | +27.37% |
| Q2 2024 | 2023-10-27 | $22.43B | $6.50B | +40.85% |
| Q1 2024 | 2023-07-28 | $23.12B | $7.78B | +50.73% |
| Q4 2023 | 2023-04-28 | $23.85B | $6.32B | +36.06% |
| Q3 2023 | 2023-01-27 | $17.69B | −$3.12B | −15.00% |
| Q2 2023 | 2022-10-28 | $15.93B | −$6.78B | −29.87% |
| Q1 2023 | 2022-07-29 | $15.34B | −$7.61B | −33.17% |
| Q4 2022 | 2022-04-29 | $17.53B | −$6.27B | −26.35% |
| Q3 2022 | 2022-01-28 | $20.81B | −$614.0M | −2.87% |
| Q2 2022 | 2021-10-29 | $22.71B | $3.16B | +16.17% |
| Q1 2022 | 2021-07-30 | $22.95B | $6.59B | +40.24% |
| Q4 2021 | 2021-04-30 | $23.80B | $2.03B | +9.32% |
| Q3 2021 | 2021-01-29 | $21.43B | −$618.0M | −2.80% |
| Q2 2021 | 2020-10-30 | $19.55B | −$2.25B | −10.33% |
| Q1 2021 | 2020-07-31 | $16.37B | −$4.33B | −20.94% |
| Q4 2020 | 2020-04-24 | $21.77B | $758.0M | +3.61% |
| Q3 2020 | 2020-01-24 | $22.04B | $2.07B | +10.38% |
| Q2 2020 | 2019-10-25 | $21.80B | $2.04B | +10.31% |
| Q1 2020 | 2019-07-26 | $20.70B | $1.40B | +7.28% |
| Q4 2019 | 2019-04-26 | $21.01B | −$1.07B | −4.84% |
| Q3 2019 | 2019-01-25 | $19.97B | $411.0M | +2.10% |
| Q2 2019 | 2018-10-26 | $19.76B | −$650.0M | −3.18% |
| Q1 2019 | 2018-07-27 | $19.30B | −$1.96B | −9.24% |
| Q4 2018 | 2018-04-27 | $22.08B | −$6.35B | −22.32% |
| Q3 2018 | 2018-01-26 | $19.56B | −$3.60B | −15.53% |
| Q2 2018 | 2017-10-27 | $20.41B | −$5.64B | −21.66% |
| Q1 2018 | 2017-07-28 | $21.26B | −$5.80B | −21.44% |
| Q4 2017 | 2017-04-28 | $28.43B | $366.0M | +1.30% |
| Q3 2017 | 2017-01-27 | $23.16B | −$7.80B | −25.21% |
| Q2 2017 | 2016-10-28 | $26.06B | −$5.26B | −16.79% |
| Q1 2017 | 2016-07-29 | $27.06B | −$3.67B | −11.93% |
| Q4 2016 | 2016-04-29 | $28.06B | −$2.70B | −8.78% |
| Q3 2016 | 2016-01-29 | $30.96B | — | — |
| Q2 2016 | 2015-10-30 | $31.31B | — | — |
| Q1 2016 | 2015-07-31 | $30.73B | — | — |
| Q4 2015 | 2015-04-24 | $30.76B | $21.85B | +245.18% |
| Q4 2014 | 2014-04-25 | $8.91B | — | — |
Medtronic net debt trends
Over the last five fiscal years, Medtronic's net debt increased from $23.80B to $25.41B, a change of $1.61B. The latest reported quarter, Q1 2027, shows $23.93B.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...